Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer

Urology

Volumn 73, Issue 5, 2009, Pages 1087-1091

  Capitanio, Umberto ^a,b   Karakiewicz, Pierre I ^a,c   Valiquette, Luc ^c   Perrotte, Paul ^c   Jeldres, Claudio ^a,c   Briganti, Alberto ^b   Gallina, Andrea ^b   Suardi, Nazareno ^b   Cestari, Andrea ^b   Guazzoni, Giorgio ^b   Salonia, Andrea ^b   Montorsi, Francesco ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY; CANCER RISK; CANCER STAGING; CORE BIOPSY; GLEASON SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 65049088199     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.048     Document Type: Article

References (28)

1. Jeldres C., Suardi N., Capitanio U., et al. High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. BJU Int 102 (2008) 463-467
2. Adolfsson J., Tribukait B., and Levitt S. The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 52 (2007) 1028-1035
3. Chun F.K., Haese A., Ahyai S.A., et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113 (2008) 701-709
4. Walz J., Gallina A., Hutterer G., et al. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 69 (2007) 88-94
5. Capitanio U., Scattoni V., Freschi M., et al. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54 (2008) 118-125
6. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
7. Chun F.K., Suardi N., Capitanio U., et al. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol (2008) Epub May 15
8. Zelefsky M.J., Yamada Y., Kollmeier M.A., et al. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 53 (2008) 1172-1179
9. Jeldres C., Suardi N., Saad F., et al. High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol 54 (2008) 97-106
10. Choo R., Pearce A., Danjoux C., et al. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for pT3 or positive resection margin after radical prostatectomy. Eur Urol 52 (2007) 1645-1650
11. Capitanio U., Briganti A., Shariat S.F., et al. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. Eur Urol 54 (2008) 717-719
12. Chun F.K., Steuber T., Erbersdobler A., et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 49 (2006) 820-826
13. Chun F.K., Briganti A., Gallina A., et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 52 (2007) 1067-1074
14. Kulkarni G.S., Lockwood G., Evans A., et al. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 109 (2007) 2432-2438
15. Scattoni V., Zlotta A., Montironi R., et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52 (2007) 1309-1322
16. Guichard G., Larre S., Gallina A., et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 52 (2007) 430-435
17. Briganti A., Chun F.K., Hutterer G.C., et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 52 (2007) 733-743
18. Trpkov K. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 52 (2007) 743-744
19. Scattoni V., Roscigno M., Raber M., et al. Initial extended transrectal prostate biopsy-are more prostate cancers detected with 18 cores than with 12 cores?. J Urol 179 (2008) 1327-1331
20. Andriole G.L. Words of wisdom. Re: extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 52 (2007) 608
21. Ficarra V., Novella G., Novara G., et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol 48 (2005) 932-937
22. Posada D., and Buckley T.R. Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst Biol 53 (2004) 793-808
23. Jeldres C., Suardi N., Walz J., et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 54 (2008) 1306-1313
24. Bastian P.J., Mangold L.A., Epstein J.I., et al. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 101 (2004) 2001-2005
25. Capitanio U., Ahyai S., Graefen M., et al. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. Urology (2008) Epub Aug 8
26. de la Taille A., Jones J.S., and Klein E.A. Open to debate-the motion: at least 18 cores are necessary to make a prostatic biopsy useful. Eur Urol 53 (2008) 659-662
27. Greene D.R. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 52 (2007) 744-745
28. Le Teuff G., Quantin C., Venot A., et al. Improving model robustness with bootstrapping-application to optimal discriminant analysis for ordinal responses (ODAO). Methods Inf Med 44 (2005) 704-711